Full history for every metric is available with a Kvantra account
ESSA Pharma Inc. (EPIX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -34 | -30 | |||||
| Net profit | $m | -10 | -23 | -37 | -35 | -27 | -29 | -25 |
| EPS reported | $ | -0.64 | -0.56 | |||||
| Operating cashflow per share | $ | -0.51 | -0.25 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.51 | -0.25 | |||||
| Free cash flow | $m | -23 | -21 | |||||
| Net debt | $m | -127 | -110 | |||||
| Book value equity | $m | 125 | 109 | |||||
| Book value per share | $ | 2.81 | 2.45 | |||||
| Number of shares | m | 44.28 | 44.39 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.15 | 0.09 | |||||
| P/S LTM | x | 0.00 | 70.12 | |||||
| P/FCF LTM | x | -11.81 | -0.46 | |||||
| EV/EBITDA LTM | x | -5.80 | 3.82 | |||||
| EV/Sales LTM | x | 0.00 | -737.37 | |||||
| Earnings Yield LTM | % | -10.64% | -116.20% | |||||
| FCF Yield | % | -8.47% | -219.42% | |||||
| Quality | ||||||||
| ROE | % | -22.91% | -9.33% | |||||
| ROIC | % | -27.55% | -11.37% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -68.99 | - | |||||
| Net Debt/EBITDA | x | 3.63 | 7.59 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -47.24% | -1151.7% | |||||
| Net debt/Equity | x | -1.02 | -1.01 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free